Compare SHAK & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | XENE |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | 2015 | 2014 |
| Metric | SHAK | XENE |
|---|---|---|
| Price | $98.40 | $41.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $117.05 | $54.09 |
| AVG Volume (30 Days) | ★ 1.7M | 978.9K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 425.42 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $1,373,459,000.00 | $7,500,000.00 |
| Revenue This Year | $18.39 | N/A |
| Revenue Next Year | $13.49 | N/A |
| P/E Ratio | $96.35 | ★ N/A |
| Revenue Growth | ★ 13.49 | N/A |
| 52 Week Low | $72.93 | $26.74 |
| 52 Week High | $144.65 | $46.60 |
| Indicator | SHAK | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 71.00 | 42.07 |
| Support Level | $88.24 | $40.00 |
| Resistance Level | $100.04 | $43.76 |
| Average True Range (ATR) | 3.59 | 1.75 |
| MACD | 1.80 | -0.41 |
| Stochastic Oscillator | 89.55 | 15.06 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.